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Abstract:  We  previously  reported  that  smenospongine,  a  sesquiterpene  aminoquinone 
isolated  from  the  marine  sponge  Dactylospongia  elegans,  showed  antiproliferative  or 
cytotoxic  activities  on  leukemia  cells.  In  this  study,  we  investigated  the  effect  of 
smenospongine on solid tumors. Since angiogenesis is well known to be closely involved 
in growth and metastasis of solid tumors, the antiangiogenic effect of smenospongine was 
determined.  We  found  that  smenospongine  inhibited  proliferation,  migration  and  tube 
formation of human umbilical vein endothelial cells (HUVEC). Moreover, the inhibitory 
activity of smenospongine on growth of solid tumor cells was investigated. Smenospongine 
inhibited the growth of 39 human solid cancer cells in vitro, with a mean Log GI50 value 
of −5.55.  In conclusion, smenospongine exhibits antitumor activity on solid tumors via 
two mechanisms,  an  antiangiogenic  effect  on  endothelial  cells  and  direct  inhibition  of 
growth of tumor cells.  
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1. Introduction 
Angiogenesis, the process of generating new blood vessels from a primitive vascular network, is 
known to be required for the growth and metastasis of solid tumors. After the size reaches 1 mm
3, a 
tumor  cannot  continue  to  grow  without  angiogenesis  [1].  Therefore,  antiangiogenesis  has  become 
known as an effective approach for therapy of solid tumors. Correspondingly, since the FDA (U.S.) 
approval of avastin in 2004 (a recombinant human monoclonal antibody against VEGF), more than 30 
inhibitors of angiogenesis have been either approved or are in clinical trials for cancer therapy [1–3]. 
We previously reported that smenospongine (Figure 1), a sesquiterpene aminoquinone isolated from 
the Indonesian marine sponge Dactylospongia elegans, showed multifaceted antitumor activities on 
leukemia  cells  [4–6].  Thus,  smenospongine  induced  G1  arrest  in  chronic  myelogenous  leukemia 
(CML) cells and apoptosis in acute myelogenous leukemia (AML) and lymphocytic leukemia [4,6]. 
Here, we present our investigations of the effect of smenospongine on solid tumors with a focus on the 
antiangiogenic  effect.  In  addition,  the  inhibitory  effect  on  the  growth  of  various  cancer  cells 
is examined.  
Figure 1. Chemical structure of smenospongine.  
 
2. Results and Discussion 
2.1. Smenospongine Inhibits Proliferation of Human Umbilical Vein Endothelial Cells (HUVECs) 
Angiogenesis is a multi-step process involving basement membrane dissolution, endothelial cell 
proliferation  and  migration,  and  new  basement  membrane  formation  [7].  To  examine  the 
antiangiogenic  activity  of  smenospongine,  we  first  determined  the  activity  on  the  proliferation  of 
HUVECs by use of WST-8 assay as reported by us previously [3].  
As  shown  in  Figure  2,  smenospongine  inhibited  the  proliferation  of  HUVECs  in  a  
concentration-dependent  manner.  The  IC50  value  was  calculated  to  be  4.9  M  (95%  confidence 
interval: 1.5 to 16 M) by use of GraphPad Prism 4.  
O
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Figure  2.  Effect  of  smenospongine  on  the  proliferation  of  human  umbilical  vein 
endothelial cells (HUVEC). 
 
2.2. Smenospongine Blocks HUVEC Migration 
To further  investigate  the antiangiogenic activity  of smenospongine, the effect on  migration of 
HUVECs  was  examined  by  use  of  a  wound  healing  assay  as  reported  [8,9].  Figure  3  shows  the 
representative  wound  healing  graphs  of  HUVECs  treated  with  DMSO  (control)  or  various 
concentrations of smenospongine for 18 h. As indicated, smenospongine blocked the migration of 
HUVECs in a concentration-dependent manner, suggesting potential antiangiogenic activity. 
Figure  3.  Effect  of  smenospongine  on  HUVEC  migration.  (A)  Representative  wound 
healing  graphs  of  HUVECs  treated  with  DMSO  (control)  or  various  concentrations  of 
smenospongine  (Sme);  (B)  Percentage  of  HUVECs  migrated  following  treatment  with 
various concentrations of smenospongine (Sme) relative to DMSO treatment alone. 
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2.3. Smenospongine Inhibits Capillary-like Tube Formation by HUVECs 
Finally, we examined the effect of smenospongine on the in vitro tube formation by HUVECs as 
reported by us previously [3]. The HUVECs were incubated in the absence or presence of 0.5 or  
2.5 M smenospongine. Eighteen hours later, the capillary-like tube structure formation on matrigel 
was  observed  under  a  microscope.  The  representative  networks  of  tube  structures  are  shown  in 
Figure 4.  Smenospongine  inhibited  tube  formation  in  a  concentration-dependent  manner,  further 
suggesting the promising antiangiogenic activity. 
Figure 4. Effect of smenospongine on tube formation by HUVECs. (A) Representative 
images depicting the tube formation by HUVECs treated with DMSO (control) or various 
concentrations of smenospongine (Sme); (B) Percentage of tube formation by HUVECS 
following  treatment  with  various  concentrations  of  smenospongine  (Sme)  relative  to 
DMSO treatment alone. 
 
2.4. Smenospongine Inhibits Growth of Various Solid Tumor Cells 
To investigate the direct activity on solid tumor cells, we determined the inhibitory effect on the cell 
growth  of  39  solid  tumor  cell  lines  (JFCR39)  by  use  of  the  sulforhodamine  B  (SRB)  assay,  as 
described by us previously [10]. The GI50 values (the concentrations of given compounds to cause 50% 
growth inhibition of cells) for each tumor cell line were obtained and the JFCR39 fingerprint was 
plotted based on the Log GI50 values [8,10,11] (Figure 5). The mean Log GI50 for all the 39 tumor cell 
lines was calculated to be −5.55. Among the cell lines, those of colorectal cancers and most lung 
cancers showed relatively higher sensitivity while those of most ovarian and breast cancers indicated 
relative resistance, suggesting such type of compound might be more applicable for treatment of the 
colorectal and lung cancers, than the ovarian and breast cancers, when approved as an anticancer drug 
in the future. Mar. Drugs 2011, 9  
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Figure 5. Effect of smenospongine on cell growth of 39 tumor cell lines. The Log GI50 
values of smenospongine for the cell lines in JFCR39 panel, and the JFCR39 fingerprint 
which  is  plotted  based  on  the  Log  GI50  values  [10],  are  indicated.  In  the  JFCR39 
fingerprint, the X-axis shows difference in logarithmic scale between the mean of Log GI50 
values for all 39 cell lines (MG-MID, expressed as 0 in the fingerprint) and the Log GI50 
for each cell line in JFCR39 panel. Columns to the right of 0 indicate the sensitivity of the 
cell lines to smenospongine and columns to the left indicate the resistance. MG-MID: mean 
of Log GI50 values for all 39 cell lines; Delta: difference between the MG-MID and the 
Log GI50 value for the most sensitive cell line; Range: difference between the Log GI50 
values for the most resistant cell line and the most sensitive cell line.  
 
3. Experimental Section 
3.1. Isolation and Identification of Smenospongine 
Smenospongine  was  isolated  from  the  marine  sponge  Dactylospongia  elegans  (collected  in 
Indonesia in 2001) as described previously [4]. The structure of smenospongine was identified by 
comparison of the mass and NMR data with those reported [12].  Mar. Drugs 2011, 9  
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3.2. Cell Lines and Cell Culture 
HUVECs  were  purchased  from  Clonetics  and  maintained  in  endothelial  cell  growth  medium-2 
(EGM2 BulletKit, Conetics) at 37 °C  in a humidified atmosphere containing 5% CO2. 
A panel of 39 human cancer cell lines termed JFCR39 [8,10], which consists of the following cell 
lines:  lung  cancer,  NCI-H23,  NCI-H226,  NCI-H522,  NCI-H460,  A549,  DMS273  and  DMS114; 
colorectal  cancer,  HCC-2998,  KM-12,  HT-29,  HCT-15  and  HCT-116;  gastric  cancer,  MKN-1,  
MKN-7, MKN-28, MKN-45, MKN-74 and St-4; ovarian cancer, OVCAR-3, OVCAR-4, OVCAR-5, 
OVCAR-8 and SK-OV-3; breast cancer, BSY-1, HBC-4, HBC-5, MDA-MB-231 and MCF-7; renal 
cancer,  RXF-631L  and  ACHN;  melanoma,  LOX-IMVI;  glioma,  U251,  SF-295,  SF-539,  SF-268,  
SNB-75  and  SNB-78;  prostate  cancer,  DU-145  and  PC-3,  were  cultured  in  RPMI  1640  medium 
supplemented  with  5%  fetal  bovine  serum  and  kanamycin  (100  U/mL)  at  37  °C   in  a  humidified 
atmosphere containing 5% CO2. 
3.3. WST-8 Assay  
Cell viability was determined using the WST-8 assay kit (Kishida Chemicals, Japan) as described 
previously by us [3]. To investigate the effect of smenospongine on the growth of HUVECs, 0.1 mL of 
cells (5 ×  10
3 cells/well) was seeded in 96-well plate and incubated in EGM2 medium at 37 °C  in a 
humidified atmosphere containing 5% CO2. Twenty-four hours later, 0.5 L of various stock solutions 
of smenospongine or DMSO was added. After further incubation for 72 h, 10 L of WST-8 was added 
to each well and further incubated. Three hours later, the absorbance at 450 nm was measured. The 
number  of  viable  cells  after  treatment  was  calculated  using  the  following  formula:  Cell  number  
(%  control)  =  100  ×   (absorbance  of  a  given  sample  −  absorbance  of  Blank  well)/(absorbance  of 
Control well − absorbance of Blank well), where the Blank well contained medium but no cells and the 
Control well contained cells but no smenospongine. The IC50 value was calculated by fitting the data 
points to a logistic curve using the GraphPad Prism 4 software. Three independent experiments were 
carried out. 
3.4. Wound Healing Assay for Cell Migration 
HUVECs  were  allowed  to  grow  to  full  confluence  in  6-well  plates  at  37  °C   in  a  humidified 
atmosphere containing 5% CO2. Then, the monolayer cells were scratched with a 1 mL pipette tip. 
Fresh  EGM2  media  were  added  with  DMSO  or  with  various  concentrations  (0.5,  2.5  M)  of 
smenospongine. After further incubation for 18 h, the migration was observed under microscope and 
photographs  were  taken.  For  quantification,  the  migrated  cells  were  counted  manually,  and  the 
percentage  inhibition  was  expressed  by  comparison  with  the  control  (treated  with  DMSO).  Two 
independent experiments were carried out. 
3.5. In Vitro Assay for Capillary-like Tube Formation 
The effect of smenospongine on tube formation in  vitro was determined following the method 
reported by us previously [3]. Briefly, matrigel (BD Biosciences, CA) was thawed overnight at 4 ° C. 
For coating, 50 L of matrigel was pipetted into each well of pre-chilled 96-well plate, and then the Mar. Drugs 2011, 9  
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plate was incubated at 37 °C  for 45 min. 0.1 mL of HUVECs (1 ×  10
5 cells/mL) was seeded in each 
well of the coated plate. 0.5 L of various stock solutions of smenospongine was added to achieve 
desired final concentrations and the cells were then incubated for 18 h at 37 ° C. The capillary-like 
tubes formed were visualized under microscope. Representative network of tube structures formed in 
each  well  was  photographed.  The  length  of  the  tubes  was  measured  for  quantification,  and  the 
percentage  of  tubes  formed  in  each  smenospongine-treated  well  relative  to  the  control  well  
(DMSO-treated  cells)  was  calculated.  Representative  data  from  2  independent  experiments,  each 
performed in triplicate, were used for analysis. 
3.6. Determination of Inhibitory Activity on Cell Growth of 39 Cancer Cell Lines and Plotting of 
JFCR39 Fingerprint 
Inhibition  of  cell  growth  of  cancer  cells  was  assessed  by  the  change  in  total  cellular  protein 
following  48  h  of  treatment  with  smenospongine,  and  was  measured  by  SRB  assay  as  described 
previously [8,10,11]. The concentration of smenospongine required for 50% growth inhibition (GI50) 
of cells was calculated. The graphic representation (termed fingerprint), the mean differential growth 
inhibition for the cells used in the JFCR39 panel, was plotted based on a calculation that uses a set of 
Log GI50 values [8,10,11].  
4. Conclusions 
Smenospongine inhibited proliferation, migration and tube formation of human endothelial cells, 
suggesting favorable antiangiogenic activity. Moreover, this compound inhibited growth of 39 cell 
lines of human solid tumors. Such results suggest smenospongine exhibits potential antitumor efficacy 
on  solid  tumors.  To  our  knowledge,  this  is  the  first  report  about  the  antiangiogenic  activity  of 
sesquiterpene  quinines,  while  some  cytotoxic  activities  of  such  compounds  were  reported  [13]. 
Smenospongine might be used as a lead compound for finding a promising anticancer drug candidate 
after structure-modification. 
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